Nicholas J. Short

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Nicholas J. Short
May 15, 2025, 13:36 | Science
Hagop Kantarjian: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared…
May 9, 2025, 12:49 | Science
The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia
ACS Journal Cancer shared a post on X: "This new review article led by Hagop…
Mar 19, 2025, 12:12 | Blog
Hagop Kantarjian: Expert recommendations on using MRD in ALL
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Mar 11, 2025, 08:03 | Drugs
Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University…
Feb 27, 2025, 11:09 | Science
Nitin Jain: Treatment-free remission in Ph+ ALL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…
Feb 26, 2025, 16:33 | Science
Hagop Kantarjian: Treatment-free remission in non-transplanted Ph+ ALL patients
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Feb 19, 2025, 10:20 | Blog
Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Dec 26, 2024, 14:37 | Insight
Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “Check…
Nov 12, 2024, 08:27 | Insight
Decitabine, venetoclax and ponatinib for advanced phase CML and Philadelphia chromosome-positive AML
Benlazar S M A, Professor of hematology, Universitary hospital of Sidi Bel Abbés, shared an…
Oct 1, 2024, 15:57 | Insight
Measurable residual disease monitoring in AML
Top Biomedical Science shared on X: “Measurable residual disease monitoring in AML: Prospects for therapeutic…
Oct 1, 2024, 11:05 | Blog,Insight
Mohamed Benlazar: General approach to patients with AML
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…
Aug 10, 2024, 12:55 | Insight
Jayastu Senapati: Utlility of baseline liver elastography in adults with B cell-ALL with liver toxicity
Jayastu Senapati shared a post on X: "Check out our paper just published in Blood…
Jul 23, 2024, 22:30 | Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Jul 23, 2024, 06:05 | Blog
Talha Badar: The role of allogeneic stem cell transplantation in Ph+ve ALL
Talha Badar shared on X: "The role of allogeneic stem cell transplantation in Ph+ve ALL? Outcome…
Jul 20, 2024, 14:27 | Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 | Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
All: 16 Posts: 1 - 100
Special Coverage